{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:45:33Z","timestamp":1791927933162,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chirurgie"],"DOI":"10.1007\/s00104-026-02595-x","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:56:59Z","timestamp":1791925019000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multimodale Therapie des lokal fortgeschrittenen und oligometastasierten \u00d6sophaguskarzinoms","Multimodal treatment of locally advanced and oligometastatic esophageal cancer"],"prefix":"10.1007","author":[{"given":"Nerma","family":"Crnovrsanin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Nienh\u00fcser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"issue":"1","key":"2595_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham\u00a0D et\u00a0al (2006) Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. New England Journal of Medicine 355(1):11\u201320. https:\/\/doi.org\/10.1056\/NEJMoa055531","journal-title":"New England Journal of Medicine"},{"issue":"22","key":"2595_CR2","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P v. Hagen","year":"2012","unstructured":"v. Hagen\u00a0P et\u00a0al (2012) Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer. New England Journal of Medicine 366(22):2074\u20132084. https:\/\/doi.org\/10.1056\/NEJMoa1112088","journal-title":"New England Journal of Medicine"},{"issue":"10184","key":"2595_CR3","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/s0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran\u00a0SE et\u00a0al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet 393(10184):1948\u20131957. https:\/\/doi.org\/10.1016\/s0140-6736(18)32557-1 (in eng)","journal-title":"Lancet"},{"issue":"17_suppl","key":"2595_CR4","doi-asserted-by":"publisher","first-page":"LBA5","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA5","volume":"43","author":"YY Janjigian","year":"2025","unstructured":"Janjigian\u00a0YY et\u00a0al (2025) Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5\u2011fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric\/gastroesophageal junction cancer (GC\/GEJC). J\u00a0Clin Oncol 43(17_suppl):LBA5\u2013LBA5. https:\/\/doi.org\/10.1200\/JCO.2025.43.17_suppl.LBA5","journal-title":"Journal of Clinical Oncology"},{"key":"2595_CR5","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2023) Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des \u00d6sophagus, Langversion 4.0.. Zugegriffen: 27. Sept. 2024 (AWMF-Registernummer: 021-023OL)"},{"issue":"6","key":"2595_CR6","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ccell.2021.05.013","volume":"39","author":"YY Janjigian","year":"2021","unstructured":"Janjigian\u00a0YY, Wolchok\u00a0JD, Ariyan\u00a0CE (2021) Eradicating micrometastases with immune checkpoint blockade: Strike while the iron is hot. Cancer Cell 39(6):738\u2013742. https:\/\/doi.org\/10.1016\/j.ccell.2021.05.013","journal-title":"Cancer Cell"},{"issue":"4","key":"2595_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa2409408","volume":"392","author":"J Hoeppner","year":"2025","unstructured":"Hoeppner\u00a0J et\u00a0al (2025) Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer. New England Journal of Medicine 392(4):323\u2013335. https:\/\/doi.org\/10.1056\/NEJMoa2409408","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"2595_CR8","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/01.sla.0000184211.75970.85","volume":"242","author":"HJ Stein","year":"2005","unstructured":"Stein\u00a0HJ, Feith\u00a0M, Bruecher\u00a0BL, Naehrig\u00a0J, Sarbia\u00a0M, Siewert\u00a0JR (2005) Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann Surg 242(4):566\u2013573. https:\/\/doi.org\/10.1097\/01.sla.0000184211.75970.85 (in eng)","journal-title":"Ann Surg"},{"issue":"5","key":"2595_CR9","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/sla.0000000000006478","volume":"280","author":"NM Wirsik","year":"2024","unstructured":"Wirsik\u00a0NM et\u00a0al (2024) Optimal Treatment Strategies for cT2 Staged Adenocarcinoma of the Esophagus and the Gastroesophageal Junction: A Multinational, High-volume Center Retrospective Cohort Analysis. Ann Surg Open 280(5):799\u2013807. https:\/\/doi.org\/10.1097\/sla.0000000000006478 (in eng)","journal-title":"Ann Surg"},{"issue":"3","key":"2595_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2503701","volume":"393","author":"YY Janjigian","year":"2025","unstructured":"Janjigian\u00a0YY et\u00a0al (2025) Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer. New England Journal of Medicine 393(3):217\u2013230. https:\/\/doi.org\/10.1056\/NEJMoa2503701","journal-title":"New England Journal of Medicine"},{"issue":"13","key":"2595_CR11","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly\u00a0RJ et\u00a0al (2021) Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. New England Journal of Medicine 384(13):1191\u20131203. https:\/\/doi.org\/10.1056\/NEJMoa2032125","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"2595_CR12","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/bjs.9437","volume":"101","author":"A Karran","year":"2014","unstructured":"Karran\u00a0A et\u00a0al (2014) Propensity score analysis of oesophageal cancer treatment with surgery or definitive chemoradiotherapy. Br J Surg 101(5):502\u2013510. https:\/\/doi.org\/10.1002\/bjs.9437 (in eng)","journal-title":"Br J Surg"},{"issue":"4","key":"2595_CR13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/s1470-2045(25)00027-0","volume":"26","author":"BJ van der Wilk","year":"2025","unstructured":"van der Wilk\u00a0BJ et\u00a0al (2025) Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial. Lancet Oncol 26(4):425\u2013436. https:\/\/doi.org\/10.1016\/s1470-2045(25)00027-0 (in eng)","journal-title":"Lancet Oncol"},{"issue":"11","key":"2595_CR14","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.annonc.2023.08.010","volume":"34","author":"K Nilsson","year":"2023","unstructured":"Nilsson\u00a0K et\u00a0al (2023) Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trial. Ann Oncol 34(11):1015\u20131024. https:\/\/doi.org\/10.1016\/j.annonc.2023.08.010 (in eng)","journal-title":"Ann Oncol"},{"issue":"4","key":"2595_CR15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa2409408","volume":"392","author":"J Hoeppner","year":"2025","unstructured":"Hoeppner\u00a0J et\u00a0al (2025) Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer. New England Journal of Medicine 392(4):323\u2013335. https:\/\/doi.org\/10.1056\/NEJMoa2409408","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"2595_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamasurg.2025.5890","volume":"161","author":"A Bondzi-Simpson","year":"2026","unstructured":"Bondzi-Simpson\u00a0A et\u00a0al (2026) Esophagectomy vs Active Surveillance in Clinical Complete Responders After Neoadjuvant Chemoradiation. JAMA Surg 161(3):275\u2013282. https:\/\/doi.org\/10.1001\/jamasurg.2025.5890","journal-title":"JAMA Surgery"},{"key":"2595_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.789155","volume":"11","author":"J Weis","year":"2021","unstructured":"Weis\u00a0J et\u00a0al (2021) Study Protocol of a\u00a0Prospective Multicenter Study on Patient Participation for the Clinical Trial: Surgery as Needed Versus Surgery on Principle in Post-Neoadjuvant Complete Tumor Response of Esophageal Cancer (ESORES). Front Oncol 11:789155. https:\/\/doi.org\/10.3389\/fonc.2021.789155 (in eng)","journal-title":"Front Oncol"},{"issue":"1","key":"2595_CR18","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","volume":"21","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger\u00a0M et\u00a0al (2020) Characterisation and classification of oligometastatic disease: a\u00a0European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. The Lancet Oncology 21(1):e18\u2013e28. https:\/\/doi.org\/10.1016\/S1470-2045(19)30718-1","journal-title":"The Lancet Oncology"},{"issue":"9","key":"2595_CR19","doi-asserted-by":"publisher","first-page":"741","DOI":"10.4251\/wjgo.v11.i9.741","volume":"11","author":"S Jamel","year":"2019","unstructured":"Jamel\u00a0S, Tukanova\u00a0K, Markar\u00a0S (2019) Detection and management of oligometastatic disease in oesophageal cancer and identification of prognostic factors: A\u00a0systematic review. World J Gastrointest Oncol 11(9):741\u2013749. https:\/\/doi.org\/10.4251\/wjgo.v11.i9.741 (in eng)","journal-title":"World J Gastrointest Oncol"},{"issue":"9","key":"2595_CR20","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaoncol.2017.0515","volume":"3","author":"SE Al-Batran","year":"2017","unstructured":"Al-Batran\u00a0SE et\u00a0al (2017) Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. JAMA Oncol 3(9):1237\u20131244. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0515 (in eng)","journal-title":"JAMA Oncol"},{"issue":"1","key":"2595_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3918-9","volume":"17","author":"SE Al-Batran","year":"2017","unstructured":"Al-Batran\u00a0SE et\u00a0al (2017) The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a\u00a0phase\u00a0III trial of the German AIO\/CAO-V\/CAOGI. BMC Cancer 17(1):893. https:\/\/doi.org\/10.1186\/s12885-017-3918-9 (in eng)","journal-title":"BMC Cancer"},{"key":"2595_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114062","volume":"204","author":"TE Kroese","year":"2024","unstructured":"Kroese\u00a0TE et\u00a0al (2024) European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4). Eur J Cancer 204:114062. https:\/\/doi.org\/10.1016\/j.ejca.2024.114062","journal-title":"European Journal of Cancer"},{"key":"2595_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102334","author":"Z Liu","year":"2025","unstructured":"Liu\u00a0Z et\u00a0al (2025) ctDNA detects residual disease after neoadjuvant chemoradiotherapy and guides adjuvant therapy in esophageal squamous cell carcinoma. Cell Rep Med. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102334","journal-title":"Cell Reports Medicine"},{"issue":"4","key":"2595_CR24","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.annonc.2020.12.010","volume":"32","author":"O Consortium","year":"2021","unstructured":"Consortium\u00a0O et\u00a0al (2021) Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling. Ann Oncol 32(4):522\u2013532. https:\/\/doi.org\/10.1016\/j.annonc.2020.12.010","journal-title":"Annals of Oncology"},{"issue":"1","key":"2595_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/s2468-1253(23)00316-3","volume":"9","author":"Q Liu","year":"2024","unstructured":"Liu\u00a0Q et\u00a0al (2024) Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 9(1):45\u201355. https:\/\/doi.org\/10.1016\/s2468-1253(23)00316-3 (in eng)","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"2595_CR26","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1038\/s41591-024-03064-w","volume":"30","author":"J Qin","year":"2024","unstructured":"Qin\u00a0J et\u00a0al (2024) Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial. Nat Med 30(9):2549\u20132557. https:\/\/doi.org\/10.1038\/s41591-024-03064-w","journal-title":"Nature Medicine"},{"issue":"4_suppl","key":"2595_CR27","doi-asserted-by":"publisher","first-page":"TPS373","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS373","volume":"40","author":"L Wang","year":"2022","unstructured":"Wang\u00a0L et\u00a0al (2022) A phase 3 randomized, double-blind, placebo-controlled, multicenter, global study of durvalumab with and after chemoradiotherapy in patients with locally advanced, unresectable esophageal squamous cell carcinoma: KUNLUN. J\u00a0Clin Oncol 40(4_suppl):TPS373\u2013TPS373. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.TPS373","journal-title":"Journal of Clinical Oncology"},{"issue":"31","key":"2595_CR28","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.2217\/fon-2021-0632","volume":"17","author":"R Yu","year":"2021","unstructured":"Yu\u00a0R et\u00a0al (2021) RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma. Future Oncol 17(31):4081\u20134089. https:\/\/doi.org\/10.2217\/fon-2021-0632 (in eng)","journal-title":"Future Oncol"}],"container-title":["Die Chirurgie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-026-02595-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00104-026-02595-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-026-02595-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:57:00Z","timestamp":1791925020000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00104-026-02595-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":28,"alternative-id":["2595"],"URL":"https:\/\/doi.org\/10.1007\/s00104-026-02595-x","relation":{},"ISSN":["2731-6971","2731-698X"],"issn-type":[{"value":"2731-6971","type":"print"},{"value":"2731-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"26 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.\u00a0Crnovrsanin und H.\u00a0Nienh\u00fcser geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}